Solid Biosciences Wins FDA Orphan Drug Status for Friedreich's Ataxia Treatment

Solid Biosciences receives FDA Orphan Drug designation for SGT-212, a dual-route gene therapy treating Friedreich's ataxia, with first patient dosed in clinical trial.